WordNet

an enzyme that dissolves the fibrin of blood clots (同)fibrinolysin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/21 05:47:59」(JST)

wiki en

Plasmin is an important enzyme (EC 3.4.21.7) present in blood that degrades many blood plasma proteins, including fibrin clots. The degradation of fibrin is termed fibrinolysis. In humans, the plasmin protein is encoded by the PLG gene.^[1]

Function

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

Plasmin is a serine protease that acts to dissolve fibrin blood clots. Apart from fibrinolysis, plasmin proteolyses proteins in various other systems: It activates collagenases, some mediators of the complement system and weakens the wall of the Graafian follicle (leading to ovulation). It cleaves fibrin, fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin, like trypsin, belongs to the family of serine proteases.

Plasmin is released as a zymogen called plasminogen (PLG) from the liver into the factor IX systemic circulation and placed into the MD5+ that leads into the lungs. Two major glycoforms of plasminogen are present in humans - type I plasminogen contains two glycosylation moieties (N-linked to N289 and O-linked to T346), whereas type II plasminogen contains only a single O-linked sugar (O-linked to T346). Type II plasminogen is preferentially recruited to the cell surface over the type I glycoform. Conversely, type I plasminogen appears more readily recruited to blood clots.

In circulation, plasminogen adopts a closed, activation resistant conformation. Upon binding to clots, or to the cell surface, plasminogen adopts an open form that can be converted into active plasmin by a variety of enzymes, including tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). Fibrin is a cofactor for plasminogen activation by tissue plasminogen activator. Urokinase plasminogen activator receptor (uPAR) is a cofactor for plasminogen activation by urokinase plasminogen activator. The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562.^[1]^[2]^[3]^[4]

Plasmin cleavage produces angiostatin.

Mechanism of plasminogen activation

Full length plasminogen comprises seven domains. In addition to a C-terminal chymotrypsin-like serine protease domain, plasminogen contains an N-terminal Pan Apple domain (PAp) together with five Kringle domains (KR1-5). The Pan-Apple domain contains important determinants for maintaining plasminogen in the closed form, and the kringle domains are responsible for binding to lysine residues present in receptors and substrates.

The X-ray crystal structure of closed plasminogen reveals that the PAp and SP domains maintain the closed conformation through interactions made throughout the kringle array .^[4] Chloride ions further bridge the PAp / KR4 and SP / KR2 interfaces, explaining the physiological role of serum chloride in stabilizing the closed conformer. The structural studies also reveal that differences in glycosylation alter the position of KR3. These data help explain the functional differences between the type I and type II plasminogen glycoforms.

In closed plasminogen, access to the activation bond (R561/V562) targeted for cleavage by tPA and uPA is blocked through the position of the KR3/KR4 linker sequence and the O-linked sugar on T346. The position of KR3 may also hinder access to the activation loop. The Inter-domain interactions also block all kringle ligand-binding sites apart from that of KR-1, suggesting that the latter domain governs pro-enzyme recruitment to targets. Analysis of an intermediate plasminogen structure suggests that plasminogen conformational change to the open form is initiated through KR-5 transiently peeling away from the PAp domain. These movements expose the KR5 lysine-binding site to potential binding partners, and suggest a requirement for spatially distinct lysine residues in eliciting plasminogen recruitment and conformational change respectively.^[4]

Mechanism of plasmin inactivation

Plasmin is inactivated by proteins such as α2-macroglobulin and α2-antiplasmin. The mechanism of plasmin inactivation involves the cleavage of an α2-macroglobulin at the bait region (a segment of the aM that is particularly susceptible to proteolytic cleavage) by plasmin. This initiates a conformational change such that the α2-macroglobulin collapses about the plasmin. In the resulting α2-macroglobulin-plasmin complex, the active site of plasmin is sterically shielded, thus substantially decreasing the plasmin's access to protein substrates. Two additional events occur as a consequence of bait region cleavage, namely (i) a h-cysteinyl-g-glutamyl thiol ester of the α2-macroglobulin becomes highly reactive and (ii) a major conformational change exposes a conserved COOH-terminal receptor binding domain. The exposure of this receptor binding domain allows the α2-macroglobulin protease complex to bind to clearance receptors and be removed from circulation.

Pathology

Deficiency in plasmin may lead to thrombosis, as clots are not degraded adequately. Plasminogen deficiency in mice leads to defective liver repair,^[5] defective wound healing, reproductive abnormalities.^{[citation needed]}

In humans, a rare disorder called plasminogen deficiency type I (Online 'Mendelian Inheritance in Man' (OMIM) 217090) is caused by mutations of the PLG gene and is often manifested by ligneous conjunctivitis.

Interactions

Plasmin has been shown to interact with Thrombospondin 1,^[6]^[7] Alpha 2-antiplasmin^[8]^[9] and IGFBP3.^[10]

References

^ ^a ^b "Entrez Gene: plasminogen".
^ Miyata T, Iwanaga S, Sakata Y, Aoki N (October 1982). "Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site". Proc. Natl. Acad. Sci. U.S.A. 79 (20): 6132–6. Bibcode:1982PNAS...79.6132M. doi:10.1073/pnas.79.20.6132. PMC 347073. PMID 6216475.
^ Forsgren M, Råden B, Israelsson M, Larsson K, Hedén LO (March 1987). "Molecular cloning and characterization of a full-length cDNA clone for human plasminogen". FEBS Lett. 213 (2): 254–60. doi:10.1016/0014-5793(87)81501-6. PMID 3030813.
^ ^a ^b ^c Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, Steer D, Cowan A, Zhang Q, Lu BG, Pike RN, Smith AI, Coughlin PB, Whisstock JC (2012). "The X-ray crystal structure of full-length human plasminogen". Cell Rep 1 (3): 185–90. doi:10.1016/j.celrep.2012.02.012. PMID 22832192.
^ Bezerra JA, Bugge TH, Melin-Aldana H, Sabla G, Kombrinck KW, Witte DP, Degen JL (December 21, 1999). "Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver". Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America) 96 (26): 15143–8. Bibcode:1999PNAS...9615143B. doi:10.1073/pnas.96.26.15143. PMC 24787. PMID 10611352.
^ Silverstein RL, Leung LL, Harpel PC, Nachman RL (November 1984). "Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator". J. Clin. Invest. 74 (5): 1625–33. doi:10.1172/JCI111578. PMC 425339. PMID 6438154.
^ DePoli P, Bacon-Baguley T, Kendra-Franczak S, Cederholm MT, Walz DA (March 1989). "Thrombospondin interaction with plasminogen. Evidence for binding to a specific region of the kringle structure of plasminogen". Blood 73 (4): 976–82. PMID 2522013.
^ Wiman B, Collen D (September 1979). "On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin". J. Biol. Chem. 254 (18): 9291–7. PMID 158022.
^ Shieh BH, Travis J (May 1987). "The reactive site of human alpha 2-antiplasmin". J. Biol. Chem. 262 (13): 6055–9. PMID 2437112.
^ Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR (August 1998). "Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3". Am. J. Physiol. 275 (2 Pt 1): E321–31. PMID 9688635.

External links

The MEROPS online database for peptidases and their inhibitors: S01.233
Plasmin at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Molecular and Cellular Biology portal

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 止血の概要 overview of hemostasis
2. 血管内皮機能および血栓溶解療法の基本的メカニズム vascular endothelial function and fundamental mechanisms of fibrinolysis thrombolysis
3. 血栓溶解異常による血栓性および出血性疾患 thrombotic and hemorrhagic disorders due to abnormal fibrinolysis
4. 血栓溶解療法後の冠動脈再梗塞の予測因子 predictors of coronary artery reocclusion following fibrinolysis thrombolysis
5. 溶連菌感染後糸球体腎炎 poststreptococcal glomerulonephritis

English Journal

Biochemical characterization of a factor X activator protein purified from Walterinnesia aegyptia venom.

Khan SU1, Al-Saleh SS.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.Blood Coagul Fibrinolysis.2015 Oct;26(7):772-7. doi: 10.1097/MBC.0000000000000336.
Factor X of blood coagulation cascade can be activated by both intrinsic and extrinsic activating complex, trypsin and some kind of snake venom. A factor X activator protein is reported in Elapidae snake venom. The aim of this study was to evaluate biochemical properties of factor X activator protei
PMID 26407136

α₂-Antiplasmin is involved in bone loss induced by ovariectomy in mice.

Shiomi A1, Kawao N2, Yano M2, Okada K2, Tamura Y2, Okumoto K3, Matsuo O2, Akagi M4, Kaji H5.
Bone.Bone.2015 Oct;79:233-41. doi: 10.1016/j.bone.2015.06.009. Epub 2015 Jun 18.
The mechanism of postmenopausal osteoporosis is not fully understood. α2-Antiplasmin (α2-AP) is the primary inhibitor of plasmin in the fibrinolytic system, but is known to have activities beyond fibrinolysis. However, its role in bone metabolism and the pathogenesis of osteoporosis remains unknow
PMID 26094563

Protective effects of polysialic acid on proteolytic cleavage of FGF2 and proBDNF/BDNF.

Hane M1, Matsuoka S1, Ono S2, Miyata S2, Kitajima K2, Sato C3.
Glycobiology.Glycobiology.2015 Oct;25(10):1112-24. doi: 10.1093/glycob/cwv049. Epub 2015 Jul 11.
Polysialic acid (polySia) is a linear polymer of sialic acid that modifies neural cell adhesion molecule (NCAM) in the vertebrate brain. PolySia is a large and exclusive molecule that functions as a negative regulator of cell-cell interactions. Recently, we demonstrated that polySia can specifically
PMID 26163659

Japanese Journal

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism

International journal of gynecological cancer 27(1), 37-43, 2017-01
NAID 120005971876

Post-infectious Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Deposits Associated with Complement Factor H Mutation

Internal Medicine 56(7), 811-817, 2017
NAID 130005530175

Factor X Deficiency with Heterozygous Mutations of Novel p.G435S and Known p.G244R in a Patient Presenting with Severe Umbilical Hemorrhage

Ｔｈｅ　Ｋｕｒｕｍｅ　Ｍｅｄｉｃａｌ　Ｊｏｕｒｎａｌ, 2017
NAID 130005439839

Related Pictures

★リンクテーブル★

リンク元	「プラスミン」「PL」「fibrinolysin」
拡張検索	「plasminogen inactivator」「plasminogen activator inhibitor-1」「α2-plasmin inhibitor deficiency」「nucleoplasmin」

「プラスミン」

Plasminogen
	PDB rendering based on 4dur.
Available structures
PDB	Ortholog search: PDBe, RCSB
List of PDB id codes
	1B2I, 1BML, 1BUI, 1CEA, 1CEB, 1DDJ, 1HPJ, 1HPK, 1I5K, 1KI0, 1KRN, 1L4D, 1L4Z, 1PK4, 1PKR, 1PMK, 1QRZ, 1RJX, 2DOH, 2DOI, 2KNF, 2L0S, 2PK4, 3UIR, 4A5T, 4CIK, 4DCB, 4DUR, 4DUU, 5HPG
Identifiers
Symbols	PLG ; DKFZp779M0222
External IDs	OMIM: 173350 MGI: 97620 HomoloGene: 55452 ChEMBL: 1801 GeneCards: PLG Gene
EC number	3.4.21.7
Gene ontology
Molecular function	• serine-type endopeptidase activity; • receptor binding; • protein binding; • serine-type peptidase activity; • protein domain specific binding; • apolipoprotein binding;
Cellular component	• extracellular region; • extracellular space; • plasma membrane; • cell surface; • platelet alpha granule lumen; • extrinsic component of external side of plasma membrane; • extracellular exosome; • blood microparticle;
Biological process	• platelet degranulation; • proteolysis; • blood coagulation; • negative regulation of cell proliferation; • negative regulation of cell-substrate adhesion; • extracellular matrix disassembly; • platelet activation; • extracellular matrix organization; • fibrinolysis; • cellular protein metabolic process; • tissue remodeling; • negative regulation of fibrinolysis; • positive regulation of fibrinolysis; • negative regulation of cell-cell adhesion mediated by cadherin;
	Sources: Amigo / QuickGO
RNA expression pattern
	More reference expression data
Orthologs
	v; t; e;